Practice Management
The Food and Drug Administration (FDA) has approved 4 updated 2026–2027 COVID-19 vaccines for the upcoming respiratory virus season. All of the new formulations have been updated for XFG variant, according to FDA, and all follow the somewhat tighter age and risk restrictions that were introduced in 2025. Prior to the 2024–2025 season, vaccination was broadly recommended for everyone aged 6 months and older. Now, a healthy 50-year-old with no underlying risk factor, for example, …
Read More
In December 2023, drug manufacturer Pfizer changed its strategic sales approach for nirmatrelvir/ritonavir (Paxlovid) by shifting to commercial sales in lieu of providing the COVID-19 antiviral drug at no-cost to patients exclusively through the federal government, according to Kaiser Health News. Some patients, such as those who are uninsured or enrolled in Medicare, Medicaid, may qualify for free prescription fills, but they need to work through an application process. What’s concerning is that nirmatrelvir/ritonavir has …
Read More